Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents.
Platinum-based polychemotherapy is widely used in the treatment of gynecological cancer. Emesis is one of the most disturbing side-effects of platinum therapy. We performed a study to evaluate and compare the emetogenic potential and the different emesis pattern after cisplatin and carboplatin under antiemetic treatment with ondansetron. One hundred and twenty-two patients with either cisplatin-containing (n = 70) or carboplatin-containing (n = 52) first-line chemotherapy were included. Treatment with cisplatin led more frequently to emesis and patients suffered from more severe emesis than carboplatin treated patients. Delayed emesis was observed after both platinum analogues but occurred more frequently and lasted longer after cisplatin.
du Bois
A
A
Department of Gynecology and Obstetrics, St. Vincentius-Krankenhaus, Karlsruhe, Germany.
Vach
W
W
Thomssen
C
C
Karck
U
U
Madjar
H
H
Prömpeler
H
H
Meerpohl
H G
HG
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008875:Middle Aged; D017294:Ondansetron / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced*
D017294:Ondansetron; D003520:Cyclophosphamide; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide